Card9 controls Dectin‐1‐induced T‐cell cytotoxicity and tumor growth in mice

Activation of the C‐type lectin receptor Dectin‐1 by β‐glucans triggers multiple signals within DCs that result in activation of innate immunity. While these mechanisms can potently prime CD8+ cytotoxic T‐cell (CTL) responses without additional adjuvants, the Dectin‐1 effector pathways that control...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of immunology 2017-05, Vol.47 (5), p.872-879
Hauptverfasser: Haas, Tobias, Heidegger, Simon, Wintges, Alexander, Bscheider, Michael, Bek, Sarah, Fischer, Julius C., Eisenkolb, Gabriel, Schmickl, Martina, Spoerl, Silvia, Peschel, Christian, Poeck, Hendrik, Ruland, Jürgen
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Activation of the C‐type lectin receptor Dectin‐1 by β‐glucans triggers multiple signals within DCs that result in activation of innate immunity. While these mechanisms can potently prime CD8+ cytotoxic T‐cell (CTL) responses without additional adjuvants, the Dectin‐1 effector pathways that control CTL induction remain unclear. Here we demonstrate that Dectin‐1‐induced CTL cross‐priming in mice does not require inflammasome activation but strictly depends on the adapter protein Card9 in vitro. In vivo, Dectin‐1‐mediated Card9 activation after vaccination drives both expansion and activation of Ag‐specific CTLs, resulting in long‐lasting CTL responses that are sufficient to protect mice from tumor challenge. This Dectin‐1‐induced antitumor immune response was independent of NK cell function and completely abrogated in Card9‐deficient mice. Thus, our results demonstrate that Dectin‐1‐triggered Card9 signaling but not inflammasome activation can potently cross‐prime Ag‐specific CTLs, suggesting that this pathway would be a candidate for immunotherapy and vaccine development. We identify Card9 as central regulator of Dectin‐1‐induced cross‐priming of cytotoxic T cells (CTLs) in mice. These Ag‐specific CTLs mediate potent antitumor immunity independent of inflammasome activity and NK cells. This pathway is a candidate for immunotherapy and vaccine development.
ISSN:0014-2980
1521-4141
DOI:10.1002/eji.201646775